Clinical Trial Update: A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating NG-641 in combination with pembrolizumab for squamous cell carcinoma of the head and neck has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• NG-641
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Akamis Bio | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 1 | Status: COMPLETED